Director of the Leukemia Program at the Abramson Cancer Center, Selina Luger, MD, examines the role of mutational analysis in the prognosis of acute myeloid leukemia (AML). A service provided by the Center for Personalized Diagnostics at Penn Medicine, the identification of gene mutations in AML involves large-scale, massively parallel DNA sequencing and chromosomal analysis. The resulting information is used to define both severity of disease and the course of treatment.
Related Links
Published
October 14, 2013
Created by
BROADCASTMED